CN111317677A - Human stem cell cosmetic formula with repairing effect on damaged cells - Google Patents
Human stem cell cosmetic formula with repairing effect on damaged cells Download PDFInfo
- Publication number
- CN111317677A CN111317677A CN201811523065.9A CN201811523065A CN111317677A CN 111317677 A CN111317677 A CN 111317677A CN 201811523065 A CN201811523065 A CN 201811523065A CN 111317677 A CN111317677 A CN 111317677A
- Authority
- CN
- China
- Prior art keywords
- stem cell
- cosmetic formulation
- human stem
- hexapeptide
- hyaluronic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/606—Nucleosides; Nucleotides; Nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Cosmetics (AREA)
Abstract
The invention discloses a human stem cell cosmetic formula with a repairing effect on damaged cells, which comprises the following components in percentage by weight: 30 to 90 percent of human body stem cell culture solution, 1 to 10 percent of pentapeptide, 1 to 10 percent of hexapeptide, 1 to 7 percent of acetyl hexapeptide-8, 1 to 7 percent of adenosine, 5 to 30 percent of hyaluronic acid and 1 to 6 percent of proteoglycan, the raw materials are selected, the human body stem cell culture solution and the hyaluronic acid are added into a stirring pot to be uniformly mixed, the stirring temperature is 50 to 65 ℃, the stirring speed is 3000 plus material rpm, the stirring time is 30 to 45 min, the pentapeptide, the hexapeptide, the acetyl hexapeptide-8, the adenosine and the proteoglycan are added after being cooled to 30 to 40 ℃, the mixture is homogenized for at least 3 times by a homogenizer, the mixture is homogenized for 3min each time and is finally kept stand to be cooled under the aseptic environment, the cosmetics produced by the formula have particularly good binding property with the human body stem cell culture solution and the human body, the components are safe, and a plurality of proteins which are compatible with the skin contained in the composition can repair the tissue damage of the skin from the cell level after penetrating into the deep layer of the skin.
Description
Technical Field
The invention relates to the technical field of regenerative medicine, in particular to a human stem cell cosmetic formula with a repairing effect on damaged cells.
Background
Cosmetics (or color cosmetics) are substances used to enhance the beauty of human body, in addition to simple cleansing products. The origin of the use of cosmetics is relatively early and widespread, especially in women with a certain economic basis. The cosmetic is chemical industry product or fine chemical product for correcting human body odor and maintaining good state. Or the skin care product is spread on any part of the surface of a human body, such as skin, hair, nails, lips and teeth, by smearing, spraying or other similar methods so as to achieve the purposes of cleaning, maintaining, beautifying, modifying and changing the appearance, the traditional cosmetics are chemicals and act on the epidermal layer of the skin, the chemicals cause various toxins, plumbum and mercury and the like to the human body after long-term use, can not repair necrotic cells at the acne mark part, and only can play a role of covering.
Disclosure of Invention
The invention aims to provide a human stem cell cosmetic formula with a repairing effect on damaged cells so as to solve the problems in the background technology.
In order to solve the technical problems, the invention provides the following technical scheme: a formula of a human stem cell cosmetic with a repairing effect on damaged cells comprises the following raw materials: human stem cell culture solution, pentapeptide, hexapeptide, acetyl hexapeptide-8, adenosine, hyaluronic acid and proteoglycan.
According to the technical scheme, the weight percentages of the raw materials are respectively as follows: 30-90% of human stem cell culture solution, 1-10% of pentapeptide, 1-10% of hexapeptide, 1-7% of acetyl hexapeptide-8, 1-7% of adenosine, 5-30% of hyaluronic acid and 1-6% of proteoglycan.
The human stem cell cosmetic formulation of claim 2, wherein the human stem cell cosmetic formulation has a repairing effect on damaged cells, and the cosmetic formulation comprises: the human body stem cell culture solution, the pentapeptide, the hexapeptide, the acetyl hexapeptide-8, the adenosine, the hyaluronic acid and the proteoglycan are respectively taken in percentage by weight: 90% of human stem cell culture solution, 1% of pentapeptide, 1% of hexapeptide, 1% of acetyl hexapeptide-8, 1% of adenosine, 5% of hyaluronic acid and 1% of proteoglycan.
The human stem cell cosmetic formulation of claim 2, wherein the human stem cell cosmetic formulation has a repairing effect on damaged cells, and the cosmetic formulation comprises: the human body stem cell culture solution, the pentapeptide, the hexapeptide, the acetyl hexapeptide-8, the adenosine, the hyaluronic acid and the proteoglycan are respectively taken in percentage by weight: 50% of human stem cell culture solution, 5% of pentapeptide, 5% of hexapeptide, 5% of acetyl hexapeptide-8, 2% of adenosine, 30% of hyaluronic acid and 5% of proteoglycan.
The human stem cell cosmetic formulation of claim 2, wherein the human stem cell cosmetic formulation has a repairing effect on damaged cells, and the cosmetic formulation comprises: the human body stem cell culture solution, the pentapeptide, the hexapeptide, the acetyl hexapeptide-8, the adenosine, the hyaluronic acid and the proteoglycan are respectively taken in percentage by weight: 30% of human stem cell culture solution, 10% of pentapeptide, 10% of hexapeptide, 7% of acetyl hexapeptide-8, 7% of adenosine, 30% of hyaluronic acid and 6% of proteoglycan.
According to the technical scheme, the human stem cells used by the human stem cell culture solution are extracted from human fat.
According to the technical scheme, the pentapeptide is a collagen hydrolysate.
According to the technical scheme, the main component of the hexapeptide is a biochemical product formed by arranging and combining six amino acids.
According to the technical scheme, the acetyl hexapeptide-8 is a neurotransmitter inhibitory peptide.
According to the above technical scheme, adenosine is a compound formed by connecting N-9 of adenine and C-1 of D-ribose through β glycosidic bond, and the phosphate ester is adenylic acid.
According to the technical scheme, the basic structure of the hyaluronic acid is large polysaccharide disaccharide unit hyaluronic acid consisting of two disaccharide units, namely D-glucuronic acid and N-acetylglucosamine, and the hyaluronic acid is mucopolysaccharide without sulfur.
According to the above technical scheme, the proteoglycan is a glycoconjugate composed of core protein and 1 or more covalently linked aminoglycans.
Compared with the prior art, the invention has the following beneficial effects: according to the human stem cell cosmetic formula with the effect of repairing damaged cells, the stem cell culture solution is extracted from human fat cells, and plant stem cells are not similar to apple stem cells, so that the human stem cell cosmetic formula has particularly good binding property with a human body; the stem cell cosmetic can penetrate into subcutaneous part, and act on epidermis from subcutaneous part; the stem cell culture solution is a biological technology product and does not contain residual components such as various toxins, lead and mercury and the like on a human body after long-term use; the stem cell culture solution can repair the tissue damage of the skin from a cell layer, such as pockmarks, and after a plurality of proteins which are compatible with the skin and contained in the stem cell culture solution permeate into the deep layer of the skin, the damaged and necrotic cells and the skin tissue can be repaired and revived again to grow the same tissue as the original tissue.
Detailed Description
The technical solutions in the embodiments of the present invention are clearly and completely described below, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
The invention provides a technical scheme that:
example 1
1) Flushing fat tissue from a liposuction source by using a D-Hanks buffer solution to remove residual blood cells and tissue fragments, putting the fat tissue into a centrifuge tube, adding 0.1% collagenase type I with the same volume into the fat tissue, putting the tissue into a 37 ℃ air bath oscillator to be digested for 30min, then standing the digested tissue for 5min, removing the upper undigested fat tissue after the tissue is layered, centrifuging the cell suspension at 1500 r/min (375g) at the lower layer for 10 min, removing supernatant to obtain a fat stem cell mass at the bottom of the centrifuge tube, re-suspending the fat stem cell mass, adjusting the density to 1 × 105mL-1, and then inoculating the fat stem cell mass into a cell culture bottle;
2): after stem cells grow over a culture bottle, washing the cells once by using a D-Hanks buffer solution, adding 2mL of mixed enzyme solution (0.25% pancreatin and 0.02% EDTA) for digestion, when the cells are observed to be obviously deformed under a microscope and shrink into a spherical shape, immediately stopping digestion by using a culture medium containing 10% fetal calf serum, slightly beating the bottom of the bottle by using a suction pipe to ensure that the cells are completely fallen and separated into suspension, placing the cell suspension on a centrifugal machine, centrifuging for 5min at 1000 r/min (167g), and finally, re-suspending the cell mass obtained by centrifugation, and adjusting the density to be proper for inoculation and passage;
3): after the culture is finished, placing the obtained mixture on a centrifuge, centrifuging for 8 min at the speed of 1000 r/min (167g), finally, re-suspending the cell mass obtained by centrifugation, and taking the upper layer stem cell culture solution;
4): the weight percentages are as follows: selecting 90% of human stem cell culture solution, 1% of pentapeptide, 1% of hexapeptide, 1% of acetyl hexapeptide-8, 1% of adenosine, 5% of hyaluronic acid and 1% of proteoglycan;
5): adding the human stem cell culture solution and hyaluronic acid into a stirring pot, and uniformly mixing at the stirring temperature of 50-65 ℃, the stirring speed of 3000-;
6): cooling the mixed solution obtained in step 5) to 30-40 ℃, adding pentapeptide, hexapeptide, acetyl hexapeptide-8, adenosine and proteoglycan, and homogenizing for at least 3 times by a homogenizer, wherein the homogenization is carried out for 3min each time;
7): standing the solution obtained in the step 6) in an aseptic environment until the solution is cooled to obtain a finished product;
example 2
1) Flushing fat tissue from a liposuction source by using a D-Hanks buffer solution to remove residual blood cells and tissue fragments, putting the fat tissue into a centrifuge tube, adding 0.1% collagenase type I with the same volume into the fat tissue, putting the tissue into a 37 ℃ air bath oscillator to be digested for 30min, then standing the digested tissue for 5min, removing the upper undigested fat tissue after the tissue is layered, centrifuging the cell suspension at 1500 r/min (375g) at the lower layer for 10 min, removing supernatant to obtain a fat stem cell mass at the bottom of the centrifuge tube, re-suspending the fat stem cell mass, adjusting the density to 1 × 105mL-1, and then inoculating the fat stem cell mass into a cell culture bottle;
2): after stem cells grow over a culture bottle, washing the cells once by using a D-Hanks buffer solution, adding 2mL of mixed enzyme solution (0.25% pancreatin and 0.02% EDTA) for digestion, when the cells are observed to be obviously deformed under a microscope and shrink into a spherical shape, immediately stopping digestion by using a culture medium containing 10% fetal calf serum, slightly beating the bottom of the bottle by using a suction pipe to ensure that the cells are completely fallen and separated into suspension, placing the cell suspension on a centrifugal machine, centrifuging for 5min at 1000 r/min (167g), and finally, re-suspending the cell mass obtained by centrifugation, and adjusting the density to be proper for inoculation and passage;
3): after the culture is finished, placing the obtained mixture on a centrifuge, centrifuging for 8 min at the speed of 1000 r/min (167g), finally, re-suspending the cell mass obtained by centrifugation, and taking the upper layer stem cell culture solution;
4): the weight percentages are as follows: selecting 50% of human stem cell culture solution, 5% of pentapeptide, 5% of hexapeptide, 5% of acetyl hexapeptide-8, 2% of adenosine, 30% of hyaluronic acid and 5% of proteoglycan;
5): adding the human stem cell culture solution and hyaluronic acid into a stirring pot, and uniformly mixing at the stirring temperature of 50-65 ℃, the stirring speed of 3000-;
6): cooling the mixed solution obtained in step 5) to 30-40 ℃, adding pentapeptide, hexapeptide, acetyl hexapeptide-8, adenosine and proteoglycan, and homogenizing for at least 3 times by a homogenizer, wherein the homogenization is carried out for 3min each time;
7): standing the solution obtained in the step 6) in an aseptic environment until the solution is cooled to obtain a finished product;
example 3
1) Flushing fat tissue from a liposuction source by using a D-Hanks buffer solution to remove residual blood cells and tissue fragments, putting the fat tissue into a centrifuge tube, adding 0.1% collagenase type I with the same volume into the fat tissue, putting the tissue into a 37 ℃ air bath oscillator to be digested for 30min, then standing the digested tissue for 5min, removing the upper undigested fat tissue after the tissue is layered, centrifuging the cell suspension at 1500 r/min (375g) at the lower layer for 10 min, removing supernatant to obtain a fat stem cell mass at the bottom of the centrifuge tube, re-suspending the fat stem cell mass, adjusting the density to 1 × 105mL-1, and then inoculating the fat stem cell mass into a cell culture bottle;
2): after stem cells grow over a culture bottle, washing the cells once by using a D-Hanks buffer solution, adding 2mL of mixed enzyme solution (0.25% pancreatin and 0.02% EDTA) for digestion, when the cells are observed to be obviously deformed under a microscope and shrink into a spherical shape, immediately stopping digestion by using a culture medium containing 10% fetal calf serum, slightly beating the bottom of the bottle by using a suction pipe to ensure that the cells are completely fallen and separated into suspension, placing the cell suspension on a centrifugal machine, centrifuging for 5min at 1000 r/min (167g), and finally, re-suspending the cell mass obtained by centrifugation, and adjusting the density to be proper for inoculation and passage;
3): after the culture is finished, placing the obtained mixture on a centrifuge, centrifuging for 8 min at the speed of 1000 r/min (167g), finally, re-suspending the cell mass obtained by centrifugation, and taking the upper layer stem cell culture solution;
4): the weight percentages are as follows: 30% of human stem cell culture solution, 10% of pentapeptide, 10% of hexapeptide, 7% of acetyl hexapeptide-8, 7% of adenosine, 30% of hyaluronic acid and 6% of proteoglycan, and selecting raw materials;
5): adding the human stem cell culture solution and hyaluronic acid into a stirring pot, and uniformly mixing at the stirring temperature of 50-65 ℃, the stirring speed of 3000-;
6): cooling the mixed solution obtained in step 5) to 30-40 ℃, adding pentapeptide, hexapeptide, acetyl hexapeptide-8, adenosine and proteoglycan, and homogenizing for at least 3 times by a homogenizer, wherein the homogenization is carried out for 3min each time;
7): standing the solution obtained in the step 6) in an aseptic environment until the solution is cooled to obtain a finished product;
according to the technical scheme, human stem cells used in a human stem cell culture solution are extracted from human fat, plant stem cells are not extracted from the human fat, such as apple stem cells and the like, so that the human stem cells are particularly good in binding with a human body, pentapeptide is a collagen hydrolysate and can promote collagen to increase skin thickness, hexapeptide is a biochemical product formed by arranging and combining six amino acids as a main component, is botulinum-like and has a function similar to botulinum toxin and can block conduction between muscles and nerves, wrinkle can be relaxed, dynamic lines and expression lines are smoothed, acetyl hexapeptide-8 is a neurotransmitter inhibiting peptide, acetyl hexapeptide-8 participates in competition of SNAP-25 at the site of a vacuole complex to influence the formation of the vacuole complex, when the vacuole complex is slightly unstable, the vacuole complex cannot effectively release neurotransmitters, so that muscle contraction is weakened, wrinkle is prevented, adenosine refers to a compound formed by connecting N-9 of adenine and C-1 of D-ribose through β glycosidic bonds, phosphate ester is a phosphate ester, a neurotransmitter and a polysaccharide, a hyaluronic acid-chitosan, a polysaccharide, a hyaluronic acid and a polysaccharide, a hyaluronic acid-chitosan, a polysaccharide, a hyaluronic acid and a hyaluronic acid-chitosan complex with a hyaluronic acid and a hyaluronic acid core unit, and a hyaluronic acid.
The working principle is that fat tissue from a fat suction source is washed by a D-Hanks buffer solution, residual blood cells and tissue fragments are removed, the fat tissue is placed in a centrifuge tube, 0.1% I-type collagenase with the same volume is added into the tissue, the tissue is placed in a 37 ℃ air bath shaker to be digested for 30min, then the digested tissue is placed for 5min, the upper undigested fat tissue is discarded after the tissue is layered, the lower layer cell suspension is centrifuged for 10 min at 1500 r/min (375g), supernatant is discarded to obtain a fat dry cell mass at the bottom of the centrifuge tube, the fat dry cell mass is resuspended with the density adjusted to 1 × 105mL-1, then the fat dry cell mass is inoculated into a cell culture bottle, after the dry cell mass is full of the culture bottle, the cells are washed once by the D-Hanks buffer solution, then 2mL mixed enzyme solution (0.25% pancreatin and 0.02% EDTA) is added into the cell mass, when the cells are observed to be obviously deformed under a microscope, after the cells are condensed into a culture bottle, the cells are immediately washed once by the D-Hanks buffer solution, the cell mass is 167-10% of the cell mass, the cell mass is added into a 0.8%, the supernatant is added into a supernatant, the supernatant is stirred for 5min, the supernatant is stirred for 10-10% of the supernatant, the supernatant is stirred for 10% of the supernatant, the supernatant is stirred for 5min, the supernatant is stirred for 5min, the supernatant is stirred, the supernatant is stirred for 5min, the supernatant is stirred, the supernatant is stirred for 5min, the supernatant is stirred.
It is noted that, herein, relational terms such as first and second, and the like may be used solely to distinguish one entity or action from another entity or action without necessarily requiring or implying any actual such relationship or order between such entities or actions. Also, the terms "comprises," "comprising," or any other variation thereof, are intended to cover a non-exclusive inclusion, such that a process, method, article, or apparatus that comprises a list of elements does not include only those elements but may include other elements not expressly listed or inherent to such process, method, article, or apparatus.
Finally, it should be noted that: although the present invention has been described in detail with reference to the foregoing embodiments, it will be apparent to those skilled in the art that changes may be made in the embodiments and/or equivalents thereof without departing from the spirit and scope of the invention. Any modification, equivalent replacement, or improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims (12)
1. A human stem cell cosmetic formulation having a repairing effect on damaged cells, characterized in that: raw materials: human stem cell culture solution, pentapeptide, hexapeptide, acetyl hexapeptide-8, adenosine, hyaluronic acid and proteoglycan.
2. The human stem cell cosmetic formulation of claim 1, wherein the human stem cell cosmetic formulation has a repairing effect on damaged cells, and the cosmetic formulation comprises: the weight percentages of the raw materials are respectively as follows: 30-90% of human stem cell culture solution, 1-10% of pentapeptide, 1-10% of hexapeptide, 1-7% of acetyl hexapeptide-8, 1-7% of adenosine, 5-30% of hyaluronic acid and 1-6% of proteoglycan.
3. The human stem cell cosmetic formulation of claim 2, wherein the human stem cell cosmetic formulation has a repairing effect on damaged cells, and the cosmetic formulation comprises: the human body stem cell culture solution, the pentapeptide, the hexapeptide, the acetyl hexapeptide-8, the adenosine, the hyaluronic acid and the proteoglycan are respectively taken in percentage by weight: 90% of human stem cell culture solution, 1% of pentapeptide, 1% of hexapeptide, 1% of acetyl hexapeptide-8, 1% of adenosine, 5% of hyaluronic acid and 1% of proteoglycan.
4. The human stem cell cosmetic formulation of claim 2, wherein the human stem cell cosmetic formulation has a repairing effect on damaged cells, and the cosmetic formulation comprises: the human body stem cell culture solution, the pentapeptide, the hexapeptide, the acetyl hexapeptide-8, the adenosine, the hyaluronic acid and the proteoglycan are respectively taken in percentage by weight: 50% of human stem cell culture solution, 5% of pentapeptide, 5% of hexapeptide, 5% of acetyl hexapeptide-8, 2% of adenosine, 30% of hyaluronic acid and 5% of proteoglycan.
5. The human stem cell cosmetic formulation of claim 2, wherein the human stem cell cosmetic formulation has a repairing effect on damaged cells, and the cosmetic formulation comprises: the human body stem cell culture solution, the pentapeptide, the hexapeptide, the acetyl hexapeptide-8, the adenosine, the hyaluronic acid and the proteoglycan are respectively taken in percentage by weight: 30% of human stem cell culture solution, 10% of pentapeptide, 10% of hexapeptide, 7% of acetyl hexapeptide-8, 7% of adenosine, 30% of hyaluronic acid and 6% of proteoglycan.
6. The human stem cell cosmetic formulation of claim 1, wherein the human stem cell cosmetic formulation has a repairing effect on damaged cells, and the cosmetic formulation comprises: the human stem cells used in the human stem cell culture solution are extracted from human fat.
7. The human stem cell cosmetic formulation of claim 1, wherein the human stem cell cosmetic formulation has a repairing effect on damaged cells, and the cosmetic formulation comprises: the pentapeptide is a collagen hydrolysate.
8. The human stem cell cosmetic formulation of claim 1, wherein the human stem cell cosmetic formulation has a repairing effect on damaged cells, and the cosmetic formulation comprises: the main component of the hexapeptide is a biochemical product formed by arranging and combining six amino acids.
9. The human stem cell cosmetic formulation of claim 1, wherein the human stem cell cosmetic formulation has a repairing effect on damaged cells, and the cosmetic formulation comprises: the acetyl hexapeptide-8 is a neurotransmitter inhibitory peptide.
10. The cosmetic formulation for human stem cells having repairing effect on damaged cells according to claim 1, wherein adenosine is a compound formed by N-9 of adenine and C-1 of D-ribose linked through β glycosidic bond, and phosphate thereof is adenylic acid.
11. The human stem cell cosmetic formulation of claim 1, wherein the human stem cell cosmetic formulation has a repairing effect on damaged cells, and the cosmetic formulation comprises: the basic structure of hyaluronic acid is a large polysaccharide disaccharide unit hyaluronic acid composed of two disaccharide units, D-glucuronic acid and N-acetylglucosamine, and is a mucopolysaccharide without sulfur.
12. The human stem cell cosmetic formulation of claim 1, wherein the human stem cell cosmetic formulation has a repairing effect on damaged cells, and the cosmetic formulation comprises: the proteoglycan is a glycoconjugate composed of core protein and 1 or more covalently linked aminoglycans.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811523065.9A CN111317677A (en) | 2018-12-13 | 2018-12-13 | Human stem cell cosmetic formula with repairing effect on damaged cells |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811523065.9A CN111317677A (en) | 2018-12-13 | 2018-12-13 | Human stem cell cosmetic formula with repairing effect on damaged cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111317677A true CN111317677A (en) | 2020-06-23 |
Family
ID=71162905
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811523065.9A Pending CN111317677A (en) | 2018-12-13 | 2018-12-13 | Human stem cell cosmetic formula with repairing effect on damaged cells |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111317677A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113440466A (en) * | 2021-05-26 | 2021-09-28 | 广州市万千粉丝化妆品有限公司 | Skin care product containing II-type proteoglycan for promoting skin repair and improving elasticity |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107184539A (en) * | 2017-04-05 | 2017-09-22 | 中山卡丝生物科技有限公司 | It is a kind of containing stem cell medium can Wash-free mask liquid preparation method and applications |
| CN107375189A (en) * | 2017-05-08 | 2017-11-24 | 广州资生生物科技有限公司 | A kind of stem cell composition and face rejuvenation cosmetic formulation |
-
2018
- 2018-12-13 CN CN201811523065.9A patent/CN111317677A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107184539A (en) * | 2017-04-05 | 2017-09-22 | 中山卡丝生物科技有限公司 | It is a kind of containing stem cell medium can Wash-free mask liquid preparation method and applications |
| CN107375189A (en) * | 2017-05-08 | 2017-11-24 | 广州资生生物科技有限公司 | A kind of stem cell composition and face rejuvenation cosmetic formulation |
Non-Patent Citations (3)
| Title |
|---|
| 佚名: "Microneedle Therapy Solution Stretch Mark Complex", 《HTTP://COSDNA.COM/CHS/COSMETIC_0AEA43668.HTML》 * |
| 佚名: "蛋白聚糖对皮肤的作用是什么？", 《HTTPS://WWW.YILIANMEITI.COM/QUESTION/1116374.HTML》 * |
| 清-云希: "乙酰基六肽-8 一种祛皱效果很好的美容多肽", 《HTTPS://ZHUANLAN.ZHIHU.COM/P/38234293》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113440466A (en) * | 2021-05-26 | 2021-09-28 | 广州市万千粉丝化妆品有限公司 | Skin care product containing II-type proteoglycan for promoting skin repair and improving elasticity |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106074304A (en) | A kind of containing hyaluronate sodium microsphere and the anti-aging cosmetics compositions with smooth out wrinkles, even skin effect of peptide | |
| CN112516058A (en) | Amino acid-loaded modified amniotic membrane mask and preparation method thereof | |
| CN105213295A (en) | A kind of recombination human source collagen protein face and preparation method thereof | |
| CN111888279B (en) | Method for promoting collagen production and corresponding medicine or cosmetic | |
| CN107375006A (en) | Surfactant containing silk protein and preparation method thereof, cleaning supplies | |
| CN109199964A (en) | One kind to peptide quintessence dew and preparation method thereof | |
| CN104706567A (en) | Method for extracting pearl fetal sac liquid from pearl fetal sac of mother pearl shellfish and product thereby | |
| CN108578352A (en) | A kind of preparation method of warming type facial mask | |
| Nilforoushzadeh et al. | Regenerative medicine applications in wound care | |
| CN109692338A (en) | A kind of collagen plaster dressing and preparation method thereof | |
| CN111317677A (en) | Human stem cell cosmetic formula with repairing effect on damaged cells | |
| KR102043444B1 (en) | Cosmetic composition for skin moisturizing with the extract of Sargassum fulvellum | |
| CN106214499A (en) | A kind of preparation method of face mask substrate material | |
| JP2021516701A (en) | Method for preparing composition for hair loss treatment | |
| CN109431853A (en) | A kind of reparation facial mask and its production technology | |
| CN109512764A (en) | Natural plants ferment essence hydrosol and the preparation method and application thereof | |
| CN108175739A (en) | A kind of stem cell composite factor anti-aging cosmetics | |
| TW201521750A (en) | Bindability enhancer for collagen fibers | |
| CN110840804A (en) | Hirudin mask cream for removing freckles and eliminating scars and repairing and preparation method thereof | |
| CN110680761A (en) | Liquid shampoo | |
| CN109078224A (en) | Skin injury repairing material and preparation method thereof | |
| KR20180119282A (en) | Biocellulose comprising solid original ingredient, composition of culture medium for manufacturing the same, and method of manufacturing the same | |
| CN112370400A (en) | Metaplexis japonica transdermal fibronectin barrier recombination repair stock solution and preparation method thereof | |
| CN113456571A (en) | PDRN-containing repairing and regenerating composition and preparation method thereof | |
| CN106539741A (en) | It is a kind of to repair silk mask of effect and preparation method thereof with scar |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20200623 |